logo
Share SHARE
FONT-SIZE Plus   Neg

Threshold Pharma Says FDA Granted Orphan Drug Designation For TH-302

Threshold Pharmaceuticals, Inc. (THLD: Quote) announced that the US Food and Drug Administration, or FDA, has granted orphan drug designation for TH-302, a hypoxia-targeted drug, for treating soft tissue sarcoma.

Barry Selick, chief executive officer of Threshold Pharma, stated, "Following our announcement on March 16 regarding the receipt of orphan drug designation in the EU, we are pleased to also have US orphan designation in place. The results of our Phase 2 study (TH-CR-403) in soft tissue sarcoma are certainly supportive of a pivotal trial underway in this difficult to treat cancer."

The company further noted that it is conducting a pivotal Phase 3 study (TH-CR-406) in soft tissue sarcoma comparing TH-302 in combination with doxorubicin against single agent doxorubicin.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Toyota Motor Corp. (TM) Tuesday said its U.S. sales for February rose 13.3 percent, as the Japanese automaker attracted new customers helped by strong marketing and plunging oil prices. Toyota's U.S. sales in February increased 13.3 percent to 180,467 units from 159,284 units a year ago. Sales... United Airlines has announced it will not accept bulk shipments of rechargeable lithium batteries, citing safety concerns. United Airlines becomes the second major airline in the U.S. to stop accepting bulk shipment of lithium batteries, after Delta Air Lines made a similar announcement last month. Tests... An online documentary by a Chinese journalist providing insight into the alarming level of smog in her country has attracted millions of views and led to wide-ranging debates among netizens.
comments powered by Disqus
RELATED NEWS
Trade THLD now with 
Follow RTT